BrAA-glycine-BG-PAB-Exatecan (Compound LD-11) is an Drug-Linker Conjugates for ADC, consisting of Exatecan and a linker. BrAA-glycine-BG-PAB-Exatecan can be conjugated with anti-ROR1 antibodies to form an ADC.\n

BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.

BODIPY TMR PI(4,5)P2 ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PS ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PI ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PE ester is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PA ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BMY-30047 is a retinoic acid derivative. BMY-30047 has topical retinoid activity. BMY-30047 has relative low local and systemic toxicity.

BMS-856 is a 17β-HSD3 inhibitor. BMS-856 inhibits enzymatic activity of 17β-HSD3, with IC50s of 60 and 300 nM respectively in the enzyme and whole cell assays.

BMS-520 is a potent, orally active and selective sphingosine-1-phosphate 1 (S1P1) agonist with an EC50 of 0.47nM. BMS-520 shows ~3400-fold selectivity over S1P3. BMS-520 demonstrates impressive efficacy in a rat model of arthritis and in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. BMS-520 can be used for arthritis and EAE research.

BMS-142 is a PDL1 inhibitor (IC50 = 96.7 nM) (kd = 13.2 nM). BMS-142 can reduce the survival rate of acute T-lymphoblastic leukemia cells and ovarian cancer cells. BMS-142 can be used in research on cancers such as acute T-lymphoblastic leukemia and ovarian cancer.

BMS-135 is a potenr, selective and ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 0.8 and 0.3 nM for CK2αandCK2α′ isoforms. BMS-135 can simulate the structure of ATP and bind to the active pocket of CK2, thereby inhibiting its serine/threonine phosphorylation function. BMS-135 can inhibit cells proliferation and shows anti-tumor effect. BMS-135 can be used for research of colon cancer.

BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM). BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer.

BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer.

BLT1-IN-1 is an orally active and selective BLT1 inhibitor with an IC50 of 8.7 nM and a Kd of 121 nM. BLT1-IN-1 exerts protective effects against acute lung injury and sepsis in in vivo models. BLT1-IN-1 can be used in research related to acute lung injury and sepsis.

BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE via a BL20 linker.

BL-1021 is an orally active ion channel blocker. BL-1021 significantly reduces symptoms of neuropathic pain without noticeable sedation or cardiac arrhythmias. BL-1021 can be used in the research of acute and chronic pain.

BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML[1].

BKI 1708 is a potent and orally active calcium-dependent protein kinase 1 (CDPK1) inhibitor (IC50 = 0.7 nM). BKI 1708 exhibits potent activity against Neospora (IC50 = 481 nM) and Toxoplasma (IC50 = 122 nM). BKI-1708 induces the formation of multinucleated complexes. BKI-1708 efficiently inhibits vertical transmission of both parasites and increases pup survival in mice.

Bis-Mal-Lysine-PEG4-DBCO (CGBS-13) is a linker for AOC drugs and can be used to synthesize AOC drugs that inhibit DMPK gene expression.

Bisdisulizole disodium is an organic chromophore with large near UV absorption cross section. Solutions of Bisdisulizole disodium dissolved in polar solvents show a strong, broad UV absorption feature centered at 340 nm.

Bilirubin ditaurine (BR-DT) is a mimetic compound of conjugated bilirubin. Bilirubin ditaurine can completely prevent the oxidation of phosphatidylcholine induced by reactive oxygen species in multilayer liposomes or micelles. Bilirubin ditaurine does not significantly decompose 18:2-OOH on its own, but it can greatly accelerate the decomposition of 18:2-OOH catalyzed by copper ions. Bilirubin ditaurine can be used to study the detoxification effect of conjugated bilirubin.

BET-IN-29 (Compound 1) is a bromodomain and the terminal motif (BET) inhibitor. BET-IN-29 can be used for the study of cancer, inflammation, metabolism, neurological diseases, and infectious diseases.

Beta-alanyl-L-arginine (β-Alanyl-L-arginine) is an intestinal microbial metabolite. Beta-alanyl-L-arginine can be used for the study of schizophrenia.

Benzyl m-hydroxycarbanilate (Compound 9) is a biologically active chemical substance and also an intermediate.

Benzobarbital is an active low-toxicity inductor of the liver monooxygenase system. Benzobarbital raises cytochrome P-450 concentration. Benzobarbital can be used in the research of post-ischemic liver disease.

Benzazepinoquinoline-spermine (Compound PA-3) is an efficient pre-miR-372 complexing agent, and it can specifically inhibit its processing mediated by Dicer. Its IC₅₀ value is 0.58 μM. Benzazepinoquinoline-spermine has a strong affinity for pre-miR-372, with a KD value of 0.11 μM. Benzazepinoquinoline-spermine also shows high activity against pre-miR-373 (IC₅₀ = 0.29 μM), but significantly reduced inhibitory activity against pre-miR-17, pre-miR-21, and pre-miR-155 (IC₅₀ being 0.84 μM, 1.43 μM, and 1.07 μM respectively). Benzazepinoquinoline-spermine can be used for cancer research.

Bentioflumin is a fluoroalkylthiobenzene acaricide with excellent leaf penetration, and its control validity period against mites exceeds 25 days. Bentioflumin can be used in studies related to mite infestation.

Belotecan-GFGG is an intermediate. Belotecan-GFGG can be used to synthesize the peptide conjugate MI-6PEG-GGFG-Belotecan. Belotecan-GFGG can be used in the research of the tumor microenvironment.

BCR-ABL-IN-13 is a dual c-Src and Abl inhibitor, with a Ki value of 0.55 μM against c-Src, 0.10 μM against wild-type Abl, and 0.40 μM against the AblT315I mutant. BCR-ABL-IN-13 exerts competitive/mixed-type inhibitory effects on wild-type Abl, and non-competitive inhibitory effects on the drug-resistant AblT315I mutant. BCR-ABL-IN-13 can be used for the research of chronic myeloid leukemia.